Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV
ART Adherence: Enhanced Counseling and Observed Therapy
Study Overview
Status
Conditions
Detailed Description
HIV is a virus that can lead to acquired immunodeficiency syndrome (AIDS), a disease that breaks down the immune system and allows for entry of life-threatening secondary infections. HIV is transmitted through the exchange of bodily fluids, primarily through sexual intercourse. Antiretroviral therapy (ART) has proven to be an effective treatment for inhibiting the replication of HIV, allowing for improved quality of life and survival. However, the long-term effectiveness of ART depends on strict adherence to a prescribed medication regimen. Previous studies have indicated that observing patients while they take their medications for a period of time can improve adherence to their prescribed drug regimens. This study will evaluate the effectiveness of enhanced counseling (EC) alone versus EC combined with modified directly observed therapy (mDOT) at improving medication adherence in people with HIV.
Participants in this 48-week study will be randomly placed into one of the following three treatment groups:
- Group 1 participants will receive standard care, which will involve the care that the clinic staff normally provide to all patients on HIV therapy.
- Group 2 participants will receive EC.
- Group 3 participants will receive EC with mDOT.
All participants will continue to take the anti-HIV medication regimen prescribed by their health care provider. However, participants will be asked to keep one medication type in a bottle that has a special Micro-Electro-Mechanical System (MEMS) cap. This electronic cap will record each time the participant opens the bottle. Participants will meet with study staff for MEMS cap data collection once weekly for the first 4 weeks, every 2 weeks up to Week 12, and then every 4 weeks thereafter.
EC will consist of 30- to 45-minute counseling sessions about medication adherence. Participants will meet in person with a counselor for the first five sessions, occurring at baseline and Weeks, 1, 2, 6, and 11. An additional five counseling sessions will be conducted by phone during Weeks 4, 9, 15, 19, and 23. Participants receiving mDOT will have their doses of HIV medication delivered to them by an mDOT worker for the first 24 weeks of treatment. Participants will select a time and location to meet with an mDOT staff member, who will then provide the daily doses of drugs and observe participants taking those drugs. Participants will meet with an mDOT worker 5 times a week from baseline to Week 16. Starting at Week 17, the number of weekly meetings will gradually taper until Week 24 when there will be no meeting and participants will return to obtaining and taking their HIV medications as done prior to study enrollment.
Evaluation visits will occur for all participants at baseline and Weeks 12, 24, 36, and 48. Evaluation sessions will last 45 minutes to 1 hour and will include questionnaires about adherence, knowledge and attitudes about HIV and HIV therapy, quality of life, support systems, health status, medical history, drug and alcohol use, and satisfaction with HIV care. Blood samples will also be taken to measure CD4 cell count and amount of virus in the blood.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Kansas University Medical Center ID Clinic
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Truman Medical Center ID Clinic
-
Kansas City, Missouri, United States, 64110
- Kansas City Free Health Clinic
-
Kansas City, Missouri, United States, 641128
- Kansas City Veterans Administration Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient at participating clinical site
- English-speaking
- Initiating new ART (new or change in therapy) or nonadherent to ART as documented by care provider's assessment, patient self-report, and consistent HIV RNA laboratory results
- Lives within 45-mile radius of participating clinical site or able to participate in observed therapy procedures
Exclusion Criteria:
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Enhanced Counseling
Participants meet with a counselor trained in motivational interviewing and cognitive behavioral techniques
|
Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23.
Counselors are trained in motivational interview technique and focus on ART medication adherence.
Other Names:
|
|
No Intervention: Standard Care
Participants receive usual clinical care provided by health care providers and they participate only in evaluation components of the study
|
|
|
Experimental: Enhanced Counseling/Modified Directly Observed Therapy
Participants receive their ART medications delivered to them by study staff and they receive the enhanced counseling
|
Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23.
Counselors are trained in motivational interview technique and focus on ART medication adherence.
Other Names:
From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose.
The frequency of observed doses begins to taper at Week 17 through to Week 24.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adherence with ART as measured by Micro-Electro-Mechanical Systems (MEMS)
Time Frame: Measured at Week 48
|
Measured at Week 48
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
HIV RNA suppression
Time Frame: Measured at Week 48
|
Measured at Week 48
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kathy Goggin, PhD, University of Missouri, Kansas City
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
Other Study ID Numbers
- R01MH068197 (U.S. NIH Grant/Contract)
- DAHBR 9A-ASGA
- PA 01 0173
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.